open access

Vol 66, No 6 (2016)
Review paper
Published online: 2017-06-12
Get Citation

Cost-effectiveness analysis of treatment of patients with colorectal cancer with FOLFOX4 and XELOX regimens

Jakub Płaczek, Małgorzata Feldheim, Bogdan Żurawski, Jerzy Krysiński
DOI: 10.5603/NJO.2016.0084
·
Nowotwory. Journal of Oncology 2016;66(6):470-476.

open access

Vol 66, No 6 (2016)
Review article
Published online: 2017-06-12

Abstract

Introduction. A comparison of the cost of an alternative treatment regimen is the basis of the rationalisation and cost effectiveness of cancer therapy. The aim of the study was to compare two alternative treatment regimens for colorectal cancer in the III and IV advancement stage (FOLFOX4 and XELOX).

Material and methods. A cost-effectiveness analysis was carried out on the basis of data collected retrospectively; considering 100 patients treated at the Oncology Centre in Bydgoszcz. A measure of the effectiveness of the therapy was the total survival time of patients. Data on the average survival time of patients has been obtained from clinical trials.

Results. The total cost of treatment per patient was 33 879.13 PLN in FOLFOX4. In XELOX the average cost per patient was 20 023.96 PLN. The endpoint, defined as the average survival time of patients treated with the FOLFOX4 scheme amounted to 27.25 months. In the case of the use of the XELOX regimen, the average survival time was 23.65 months. Incremental costs for additional units as a result of using the more expensive treatment regimen were estimated as 46 183.47 PLN.

Conclusions. The comparison of the two treatment regimens for colorectal cancer in stage III and IV, which were used in the Oncology Centre in Bydgoszcz, showed that the more expensive but more efficient treatment was FOLFOX4.

Abstract

Introduction. A comparison of the cost of an alternative treatment regimen is the basis of the rationalisation and cost effectiveness of cancer therapy. The aim of the study was to compare two alternative treatment regimens for colorectal cancer in the III and IV advancement stage (FOLFOX4 and XELOX).

Material and methods. A cost-effectiveness analysis was carried out on the basis of data collected retrospectively; considering 100 patients treated at the Oncology Centre in Bydgoszcz. A measure of the effectiveness of the therapy was the total survival time of patients. Data on the average survival time of patients has been obtained from clinical trials.

Results. The total cost of treatment per patient was 33 879.13 PLN in FOLFOX4. In XELOX the average cost per patient was 20 023.96 PLN. The endpoint, defined as the average survival time of patients treated with the FOLFOX4 scheme amounted to 27.25 months. In the case of the use of the XELOX regimen, the average survival time was 23.65 months. Incremental costs for additional units as a result of using the more expensive treatment regimen were estimated as 46 183.47 PLN.

Conclusions. The comparison of the two treatment regimens for colorectal cancer in stage III and IV, which were used in the Oncology Centre in Bydgoszcz, showed that the more expensive but more efficient treatment was FOLFOX4.

Get Citation

Keywords

FOLFOX4, XELOX, cost-effectiveness analysis, colorectal cancer

About this article
Title

Cost-effectiveness analysis of treatment of patients with colorectal cancer with FOLFOX4 and XELOX regimens

Journal

Nowotwory. Journal of Oncology

Issue

Vol 66, No 6 (2016)

Article type

Review paper

Pages

470-476

Published online

2017-06-12

DOI

10.5603/NJO.2016.0084

Bibliographic record

Nowotwory. Journal of Oncology 2016;66(6):470-476.

Keywords

FOLFOX4
XELOX
cost-effectiveness analysis
colorectal cancer

Authors

Jakub Płaczek
Małgorzata Feldheim
Bogdan Żurawski
Jerzy Krysiński

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media sp. z o.o. VM Group sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl